Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin, type II cytoskeletal 80 (KRT80) is a type II intermediate filament protein that is a structural component of the cytoskeleton in human epithelial cells[1][2][4][3]. It provides mechanical support and plays essential roles in processes such as cell differentiation, apoptosis, migration, adhesion, and positioning of organelles[1][2][4]. KRT80 is widely expressed in nearly all epithelial tissues and can interact with other type II keratins to form heterodimers. Uniquely, although encoded as an epithelial keratin, KRT80 is structurally more similar to type II hair keratins[1][4]. KRT80 is notably overexpressed in many cancers—including colorectal and gastric cancer—where it promotes proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT), frequently via AKT pathway activation[1][2]. High KRT80 expression is associated with poor prognosis and lower disease-free survival in cancer patients, making it an emerging biomarker and potential therapeutic target in oncology[1][2]. Currently, no clinically approved drugs are known to directly target KRT80. Diseases linked to mutations in KRT80 include Pachyonychia Congenita 1[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin, type II cytoskeletal 80 (KRT80).